Severe setback for research on lipoprotein (a): its reduction does not prevent the risk of cardiovascular problems

Pelacarsen, a drug aimed at lowering lipoprotein(a), failed in a Phase III trial to reduce severe cardiovascular events. Despite significantly lowering Lp(a) levels, the incidence of major cardiovascular events was similar to placebo. Experts express surprise at the results, questioning the causal role of Lp(a) in cardiovascular disease. Future research may explore other treatments, and the importance of measuring Lp(a) levels remains for assessing cardiovascular risk. Age at intervention may influence outcomes, highlighting the need for early prevention of atherosclerosis.